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Breast cancer is a heterogeneous disorder in which most tumors display some degree of aneuploidy, especially those at later
stages of the disease. Aneuploidy and associated chromosome instability may be important in the progression of mammary
tumorigenesis. Aneuploidy is prevented during normal cell division in part through regulation of a mitotic spindle checkpoint
where mitotic arrest prevents segregation of misaligned chromosomes into daughter cells at anaphase. Mitotic arrest genes,
including the MAD family, which was originally characterized in yeast, help regulate normal function of the mitotic spindle
checkpoint. Decreased expression of the human gene MAD2L1 was previously reported in a breast cancer cell line exhibiting
chromosome instability and aneuploidy. To explore further the potential role of MAD2L1 in breast cancer, we analyzed
MAD2L1 gene expression in 13 minimally to grossly aneuploid human breast cancer cell lines and found significant differences
of expression in three lines. Sequence analysis of MAD2L1 cDNA in these as well as nine additional aneuploid breast cancer
and five immortalized normal human mammary epithelial cell lines revealed one heterozygous frameshift (572 del A) mutation
in a cancer cell line that demonstrated a high level of transcript expression. In addition, two 39UTR sequence variants were
noted in breast cancer cell lines. The 572 del A mutation creates a truncated MAD2 protein product. Further functional studies
in primary breast tumors are therefore warranted to determine the potential role MAD2L1 may play in breast cancer.
© 2000 Wiley-Liss, Inc.
Breast cancer continues to be a significant cause
of morbidity and mortality in the Western world. It
is widely hypothesized that breast cancer arises
from the clonal accumulation of mutations in genes
regulating normal cellular growth, akin to the ele-
gant multistep paradigm first recognized in colorec-
tal cancer (Fearon, 1997). The multistep path-
way(s) in breast cancer remains poorly understood,
however, especially for the common heterogeneous
sporadic mammary neoplasms in which no predis-
posing germline mutations exist. Examination of
mutation rates in somatic cells implies that the
clonal acquisition of sufficient mutations to pro-
mote multistep tumorigenesis is improbable during
a human lifetime (Loeb, 1991; Orr-Weaver and
Weinberg, 1998). Additional molecular mecha-
nisms may be required to drive the cell toward a
malignant phenotype. In some solid tumors, espe-
cially some colon cancers, malignant progression is
accelerated when the cells’ genomes are rendered
unstable by alterations in genes that have defective
DNA mismatch repair ability, allowing the rapid
accumulation of mutations to drive tumorigenesis
(Lengauer et al., 1998). Most breast cancers do not
harbor mismatch repair defects to account for in-
creased genomic instability; however, a majority
exhibit some degree of aneuploidy, especially at
later stages of the disease (Shackney et al., 1995).
The significance of observable aneuploidy in breast
cancer is not well established, but correlates with
both disease aggressiveness (Tsuda et al., 1998) and
chromosomal instability (CIN) (Duesberg et al., 1998;
Lengauer et al., 1998). Molecular defects resulting in
CIN and aneuploidy, therefore, may contribute to the
progression of mammary tumorigenesis.
Normally, a mitotic spindle checkpoint monitors
proper microtubule attachment to chromosomes
prior to progression through mitosis to yield eu-
ploid daughter cells through regulation of the an-
aphase promoting complex (APC) (Lengauer et al.,
1998). Yeast genes important in the spindle check-
point include members of the BUB (budding un-
inhibited by benomyl) and MAD (mitotic arrest-
deficient) families. Early evidence suggests that
alterations of the human homologs of these genes
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may in fact be associated with human malignancy.
Reduced expression of the human MAD2L1 tran-
script was previously reported in T47D, a human
breast cancer cell line that demonstrated a defec-
tive mitotic arrest response (Li and Benezra, 1996).
However, further studies exploring the potential
role of MAD2L1 in breast cancer are lacking.
MAD2L1, located on 4q27, encodes a 205-amino-
acid protein that is associated with the kinetochore
of unattached chromosomes and inhibits APC, but
is absent when chromosomes are correctly aligned
on the metaphase plate (Chen et al., 1996). MAD2
protein exists as a monomer or as a tetramer, with
the latter state likely being the active form that
inhibits APC (Fang et al., 1998a, 1998b). Oligomer-
ization of MAD2 or a conformation associated with
the MAD2 tetrameric state may transduce the mi-
totic checkpoint signal (Wolf and Jackson, 1998).
Mutations in BUB1, a human homolog to another
yeast mitotic arrest gene, demonstrated functional
importance in human colorectal cancers exhibiting
chromosome instability. Specifically, dominant
negative mutant BUB1 alleles in colorectal tumor
cell lines promoted CIN and were associated with
abnormal mitotic checkpoint responses (Cahill et
al., 1998). Lee et al. (1999) recently demonstrated
that mutations in Bub1 and Mad3L mitotic spindle
checkpoint genes can potentiate growth and cellu-
lar transformation in a study of Brca2-deficient mu-
rine cells. It would appear that defects in Brca2 and
mitotic spindle checkpoint genes could work to-
gether to overcome checkpoint controls in the cell
cycle, thereby promoting cell division, resulting in
aneuploidy, and driving tumorigenesis. These find-
ings suggest that similar alterations in other mitotic
arrest genes may play roles in breast cancer by
abolishing the normal mitotic checkpoint control
mechanism. Loss of normal control would allow
mammary epithelial cells to divide even when
chromosomes are not correctly attached to the spin-
dle, giving rise to aneuploidy and chromosomal
instability that may accelerate tumor progression.
Because decreased expression of MAD2L1 was
previously described in one breast cancer cell line
(Li and Benezra, 1996), we elected to explore fur-
ther involvement of MAD2L1 in breast cancer. We
analyzed MAD2L1 transcript expression in 13
breast cancer cell lines to help determine the fre-
quency of altered expression of MAD2L1 in breast
cancer. Given that many of these well-character-
ized cell lines are markedly aneuploid, we hypoth-
esized that they would be likely to have the highest
probability of harboring alterations in MAD2L1 if,
indeed, alterations of this gene were important in
aneuploidy and breast cancer.
Ten SUM breast cancer cell lines, 12 American
Type Culture Collection breast cancer cell lines,
and 5 human papilloma virus (HPV) immortalized
normal breast cell lines were initially available for
study. SUM breast cancer and normal breast cell
lines were developed at the University of Michigan
Comprehensive Cancer Center by Stephen P.
Ethier and are well characterized with regard to
their cytogenetic phenotype (Ethier et al., 1993,
1996; Garcia et al., 1997; Sartor et al., 1997; Flana-
gan et al., 1998; Forozan et al., 1998; Ignatoski and
Ethier, 1998). These cell lines were cultured in
Ham’s F-12 medium, either serum-free or with 5%
FBS, in the presence of Fungizone and gentamy-
cin. In addition, insulin, hydrocortisone and epider-
mal growth factor or choleratoxin were included in
the medium (see http://p53.cancer.med.edu/clines/
clines/elab.html). The breast cancer cell line
CAL51 was kindly provided by Dr. J. Gioanni,
Nice, France (Gioanni et al., 1990) and grown in
Dulbecco’s modified Eagle medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS).
The remaining breast cancer cell lines were main-
tained according to the American Type Culture
Collection instructions.
Total RNA was isolated from all cell lines at ap-
proximately 80% confluency using Trizol reagent ac-
cording to the manufacturer’s instructions (Gibco-
BRL, Grand Island, NY). For Northern blot analysis,
10 mg of total RNA from 13 breast cell lines was
fractionated on 1.25% agarose gel and transferred to
Hybond N1 (Amersham Life Science, Piscataway,
NJ) in 10 3 SSC. A 1.3-kb MAD2L1 full-length RT-
PCR product (5-TGTCCGCGGAGTGGAAGC-3;
5-ACTTTATTTCCTCACTTTCA-3) and a 407-bp
GAPDH RT-PCR product (5-GGGAGCCAAAA-
GGGTCATCA-3; 5-TTTCTAGACGGCAGGTC-
AGGT-3) were labeled by random priming with
[a32P] dCTP. Hybridization was performed at 60°C
overnight in Church buffer (1-mM EDTA, 0.5-M
NaHPO4, 7% SDS). Filters were washed at 60°C in
2 3 SSC, 0.1% SDS, and exposed to Kodak XAR-5
film.
By Northern blot analyses, all MAD2L1 tran-
scripts were of the anticipated 1.4-kb size, and no
aberrant transcripts were detected. MAD2L1 ex-
pression levels were visually assessed as compared
to ethidium bromide-stained gels for loading and
also standardized against glucose-3-phosphate-de-
hydrogenase (GAPDH) gene expression levels by
calculating the ratio of MAD2L1 to GAPDH for all
cell lines as quantified by densitometry (data not
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shown, Alpha Innotech IS-1000 Digital Imaging
System, San Leandro, CA). Densitometry was used
to confirm our visual observations in all cases. The
ratio of MAD2L1 expression to GAPDH expression
in an immortalized normal mammary epithelia line
with a functionally normal mitotic checkpoint in
response to chemical disruption of the mitotic spin-
dle microtubules by nocodazole, 5-24 HPV, was
determined to be 0.8 (data not shown). This
MAD2L1-to-GAPDH transcript expression ratio was
nearly identical to the ratios observed for the can-
cer cell lines MCF7 and SK-BR-3 (lanes 7 and 9,
Fig. 1). The levels of MAD2L1 expression in the
BT-20 and SUM1315MO2 lines (lanes 3 and 13,
Fig. 1) were similar but slightly less with ratios of
MAD2L1 to GAPDH closer to 0.6. In the MDA-MB-
361, MDA-MB-435s, BT-474, BT-549, DU4475,
and Hs578T lines (lanes 1, 2, 4, 5, 6, and 10, Fig. 1),
MAD2L1 expression appeared comparatively low
by visual analysis and MAD2L1-to-GAPDH expres-
sion ratios as determined by densitometry were
calculated to be , 0.5. As shown, MAD2L1 expres-
sion was most dramatically reduced in lines MDA-
MB-435 and Hs578T where the MAD2L1-to-
GAPDH ratios were , 0.1. Compared to other lines,
CAL51, SUM149PT, and SUM159PT demon-
strated increased MAD2L1 expression as deter-
mined by both visual observation and densitometry
analysis (lanes 8, 11, 12, Fig. 1). Most significantly,
CAL51 demonstrated significantly increased ex-
pression with an MAD2L1-to-GAPDH ratio . 3.0.
The physiologic importance of variable expression
in these cell lines is difficult to assess because
appropriate matched control samples were not
available for analysis. It is possible that variable
expression could be due to differences in cell cycle
states. Other factors such as the rate of cell growth
when the cells were harvested for RNA isolation
could also contribute to the variable levels of tran-
script expression, but all attempts were made to
minimize this possibility by harvesting the cells at
80% confluence. Southern blot analysis did not
reveal any structural changes that could explain the
variability in MAD2L1 expression levels in these
breast cancer cell lines (data not shown). Given the
variable expression and the difficulty inherent in
interpreting transcript expression analysis without
matched controls, we elected to analyze these and
additional breast cancer lines further for mutations.
We conducted a mutational analysis of the
MAD2L1 gene in 22 breast cancer cell lines and 5
HPV immortalized normal breast epithelial cell
lines by direct sequencing of RT-PCR amplified
MAD2L1 gene products to determine whether
there were alterations in the coding region. RT-
PCR was performed with 5 mg of total RNA using
the SuperScript Preamplification System (Gibco-
BRL) and oligo dT primers. A 1.3-kb fragment
encompassing the conceptual translation start site
of the MAD2L1 open reading frame and the 39
untranslated region (UTR) was amplified using
primers 5-TGTCCGCGGAGTGGAAGC-3 (F1,
Fig. 2) and 5-ACTTTATTTCCTCACTTTCA-3
(R1, Fig. 2) (Krishnan et al., 1998). This avoided
the amplification of a pseudogene homologous to
the 59 region of MAD2L1 located on chromosome
14 (Krishnan et al., 1998). PCR products were pu-
rified using the High Pure PCR Product Purifica-
tion Kit (Boehringer Mannheim, Indianapolis, IN)
and were quantified fluorometrically. Sequencing
was performed using a Thermosequence Cycle Se-
quencing Kit (Amersham Life Science) with the
following primers: 5-GCGCGTGCTTTTGTT-
TGT-3 (S1), 5-CCAGAGAAAAGTCTCAGAAA-
GC-3 (S2), and 5-GGCAGAAATGTCACCGTA-
GC-3 (S3) (Fig. 2). Reaction products were sepa-
rated by electrophoresis on 6% polyacrylamide urea
gels in 1 3 glycerol tolerant buffer (USB). Gels
were dried and exposed to Kodak XAR-5 film.
MAD2L1 cDNA was generated from all of the
breast cancer cell lines, and one major band of
expected size 1.3 kb was amplified for each cell
line. A deletion of A at nucleotide 572 within the
coding region (Genbank accession number
U31278) was identified in the CAL51 breast cancer
cell line leading to a premature stop codon (Fig. 3).
This deletion was confirmed from two indepen-
dent cDNA samples. Because the mutant and nor-
mal sequences were obtained from CAL51 cDNA
and the primers used to amplify the MAD2L1 gene
from cDNA do not amplify genomic DNA, the
expressed transcript contained both wild-type and
mutant alleles. The loss of nucleotide 572 causes a
Figure 1. Expression analyses of MAD2L1 in breast cancer cell lines.
A: A 32-P-labeled full-length RT-PCR MAD2L1 probe detects a 1.4-kb
band for each of the breast cancer cell lines: MDA-MB-361 (lane 1),
MDA-MB-435s (lane 2), BT-20 (lane 3), BT-474 (lane 4), BT-549
(lane 5), DU4475 (lane 6), MCF7 (lane 7), CAL51 (lane 8), SK-BR-3
(lane 9), Hs578T (lane 10), SUM149PT (lane 11), SUM159PT (lane
12), and SUM1315MO2 (lane 13). B: GAPDH RT-PCR probe illustrates
RNA loading.
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frameshift mutation, resulting in the substitutions
of the subsequent 27 amino acids after residue 167.
In addition, there is loss of the terminal 13 amino
acids due to the premature stop at codon 193. This
has significant consequences for the MAD2 protein
because it has been reported that the 10 terminal
amino acids of MAD2 contain the region necessary
for binding to CDC20 and oligomerization (Luo et
al., 2000). It has also been demonstrated in yeast
that this C-terminal tail is involved in Mad1 and
Mad2 binding, which is required for checkpoint
function (Fang et al., 1998a). No nucleotide
changes were detected in the first 500 nucleotides
of the coding region. This sequence has been re-
ported to contain conserved surface residues that
form two distinct patches of a central b-sheet in the
MAD2 protein (Luo et al., 2000).
Two sequence variants were also detected in the
39UTR of the MAD2L1 gene in breast lines. Eight
of 27 breast lines exhibited a heterozygous G-to-A
transition at nucleotide 751 (Table 1). MDA-MB-
157 carried a T-to-C transition at nucleotide 837
(Table 1). To examine further the prevalence of
the sequence variants in other cancer lines, se-
quence analysis of MAD2L1 was performed on
cDNA from 24 nonbreast cancer cell lines (ATCC).
The 751 (G-to-A) transition was observed in one
allele of seven cell lines (total 15 of 51 breast and
nonbreast cancer cell lines), suggesting that this
sequence variant is most likely to be a polymor-
phism. No other cell lines carried the 837 (T-to-C)
transition. In addition, four single sequence vari-
ants were detected in MAD2L1 transcript in the
nonbreast cancer cell lines. Three of these cell
lines, U-87MG, U-373MG, and MDA-H2774, ex-
hibited an A-to-G transition at the wobble nucleo-
tide 503 for proline 143. An A-to-G transition at
nucleotide 642 changed isoleucine to valine at
codon 190 in cell line U-87MG (Fig. 3). Because
both amino acids have similar characteristics, this
substitution may represent a benign polymor-
phism. At nucleotide positions 709 and 780 in the
39UTR, A-to-G substitutions were detected in
U-87MG and OV-1063.
To investigate whether the MAD2L1 mutation
(572 del A) detected in the breast cancer cell line
CAL51 generated a truncated MAD2 protein prod-
uct as predicted, we carried out in vitro transcrip-
tion/translation of MAD2. The 1.3-kb RT-PCR
products from CAL51 were TA subcloned into
PCR II–TOPO vector (Invitrogen, Carlsbad, CA).
Sequencing confirmed the presence or absence of
the mutation. Wild-type and mutant inserts of
MAD2L1 were directionally cloned into pcDNA3.1
expression vector (Gibco-BRL) using BamH1 and
Xba1 sites. Correct sequence orientation was con-
firmed by sequencing. In vitro transcription/trans-
lation of the cloned mutant and wild-type copies of
MAD2L1 was performed using the TNT T7 Quick
Coupled Transcription/Translation System (Pro-
mega, Madison, WI) according to the manufactur-
er’s instructions. Reaction products were electro-
phoresed on a 15% SDS-PAGE gel, transferred to
Hybond-P nitrocellulose (Amersham Life Science)
by semidry transfer, immunoblotted with primary
goat MAD2 IgG polyclonal (1:1,000, NH3 termi-
nus) antibody and secondary antigoat IgG HRP-
conjugated antibody (1:8,000) (Santa Cruz Biotech-
nology, Santa Cruz, CA), and visualized by
chemiluminescence using Supersignal West Pico
ECL kit (Pierce, Rockford, IL). As predicted, the
mutant allele resulted in a truncated protein ap-
proximately 22.2 kD in size (Fig. 4), a difference of
1.3 kD from the predicted wild-type MAD2 pro-
tein of 23.5 kD (Li and Benezra, 1996). Analyses by
Western blot of 150 mg of CAL51 cell lysate did not
Figure 2. MAD2L1 gene structure. Shaded boxes indicate the five
exons. Primers used for PCR (F1, R1) and sequencing (S1, S2, S3) are
shown by horizontal arrows. Black triangle indicates 572 del A in
CAL51 breast cancer cell line; open triangles indicate sequence variants
found in breast cancer and nonbreast cancer cell lines. Striped triangle
denotes a frequently found sequence variant, and dotted triangle de-
notes a sequence variant in a nonbreast cancer cell line (U-87MG) that
results in an isoleucine to valine substitution. Figure not drawn to scale.
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reveal an endogenous truncated protein (data not
shown), suggesting that the truncated protein may
be unstable or that it is expressed at very low levels
undetectable by this analysis.
MAD2 forms a ternary complex with CDC20
and APC. Binding of MAD2 inhibits activation of
the APC by CDC20, causing arrest at metaphase
during the cell cycle (Fang et al., 1998a). Inhibition
of the APC ensures fidelity of sister chromatid
separation by controlling defects in the kinetochore
attachment to the spindle and correct initiation of
anaphase. In vivo evidence suggests that MAD2
exists as a monomer and a tetramer (Fang et al.,
1998a). Both forms bind to CDC20, but in vitro
studies demonstrate that only the tetramer inhibits
CDC20 activation of the APC (Fang et al., 1998a).
The 572 del A of MAD2 in the CAL51 breast
cancer cell line is predicted to cause a change in
20% of the carboxy end of the protein. Although
the function of this mutation has not yet been
characterized, given that MAD2 functions as a tet-
ramer, one abnormal allele could have a dominant
negative effect. Loss of function of MAD2 through
a dominant negative mutation could promote an-
euploidy by abrogating the mitotic spindle check-
point. Truncated MAD2 would most likely un-
dergo a conformational change that alters binding
to CDC20 and therefore regulation of the APC.
Similarly, the truncated protein may bind to
CDC20, but is unable to prevent degradation of
anaphase inhibitor and activation of the CDC20-
APC complex because it cannot oligomerize to
form the active protein. Alternatively, the trun-
cated protein may be unstable and expressed at
relatively low levels. In CAL51 cells, both mutant
and wild-type MAD2L1 alleles are expressed, as
suggested by Northern blot analysis and RT-PCR.
Northern blot data suggested an increased level of
MAD2L1 transcript expression, potentially reflect-
ing compensatory overexpression due to lack of
normal function. Given this, it is currently unclear
how the heterozygous 572 del A mutation would
effect the mitotic checkpoint and/or cellular prolif-
eration in CAL51 cells. Studies of this mutation
through in vitro and in vivo model systems will be
needed to determine if the mutation can in fact
function as a dominant negative alteration. Pres-
ently, it is also unclear how the expression of the
MAD2L1 gene is regulated during the cell cycle.
Overexpression of MAD2 in yeast causes mitotic
arrests at metaphase (He et al., 1997) and would
suggest an exertion of spindle checkpoint control.
Therefore, increased expression may be a mecha-
nism that compensates for loss of normal function
Figure 3. MAD2L1 sequence variants. A: Breast cancer cell line
DU4475 has a change at nucleotide 751 (G-to-A) also detected in eight
breast cancer cell lines and one nonbreast cancer cell line. B: Deletion
of A at nucleotide position 572 (572 del A) in CAL51 breast cancer cell
line causes a frameshift and a premature stop codon; thus, apparent
slippage of sequence of one allele is noted (mutant sequence TTGTAC-
CTGAAAAATGGGAAGAGTC . . . ; underlined base is deleted from
one allele). C: A transition at nucleotide 642 (A-to-G) detected in U-87
MG nonbreast cell line. Arrows points to bands corresponding to base
changes; a normal sequence is included for comparison.
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of the mutant protein in CAL51 cells. CAL51 cells
are minimally aneuploid, near-diploid in many
cells, with a high proportion of tetraploid cells.
Interestingly, analysis of gastrointestinal preneo-
plastic lesions suggests that tetraploidization may
be one of the earliest consequences of asymmetric
chromosome segregation secondary to dysregula-
tion of genes that normally exert active checks on
chromosome stability (Giaretti, 1997). Further analy-
sis of CAL51 cell response to microtubule inhibitors
is warranted for investigation of this hypothesis.
Whereas variable levels of transcript expression
may be of no physiologic consequence, the appar-
ent increased level of MAD2L1 transcript expres-
sion in a breast cancer line with a frameshift mu-
tation suggests that they may reflect physiologic
regulation. The detection of other breast cancer
cell lines demonstrating variable levels of transcript
expression despite no coding region mutations sug-
gests that there could be mutations in transacting
factors or cis-sequence elements that regulate
MAD2L1 expression levels. Such factors could in-
volve the 39UTR, where most of the sequence
variants were located, but this remains to be deter-
mined. There are no clear correlations between
ploidy status, transcript expression levels, and
39UTR variants that can be made from this limited
study. Interestingly, however, two of the breast
cancer cell lines (MCF7 and SK-BR-3) that dem-
onstrated MAD2L1 transcript expression levels
closest to that seen in an HPV immortalized normal
mammary epithelial cell line (5-24-HPV) did not
have any identifiable sequence alterations. Of the
eight breast cancer cell lines with comparatively
less observable MAD2L1 expression, three of the
lines do exhibit 39UTR sequence alterations. Of
the two lines suggesting increased MAD2L1 ex-
pression that lack an exon mutation, one line,
SUM159PT, has the same 751 (G-to-A) transition
in the 39UTR region that is seen in two lines with
decreased MAD2L1 expression. Factors such as post-
translation modification and different cell cycle states
may also affect MAD2L1 expression. It is also possible
that RT-PCR–based mutation analysis may not al-
ways detect an existing mutation in breast cancer
lines with decreased MAD2L1 expression, especially
if the mutant allele is not expressed at high enough
levels. However, the fact that we did identify a se-
TABLE 1. Mutational Analysis of MAD2L1 in Immortalized Normal and Transformed Breast Cancer Cell Lines
Cell line
Lanes as on
Northern blot Ploidy status Base change Mutation status
MCF-10a Diploid No change
4–12 HPVa Diploid 751 (G 3 A)b Heterozygous
5–24 HPVa Diploid No change
11-6 HPVa Diploid No change
11–21HPVa Diploid 751 (G 3 A)b Heterozygous
BT-20 Lane 3 Hyperdiploid No change
BT-474 Lane 4 Aneuploid No change
BT-549 Lane 5 Aneuploid No change
CAL51 Lane 8 Diploid to tetraploid 572 (del A)c Heterozygous
DU4475 Lane 6 Aneuploid 751 (G 3 A)b Heterozygous
Hs 578T Lane 10 Aneuploid 751 (G 3 A)b Heterozygous
MCF-7 Lane 7 Hypertriploid to hypertetraploid No change
MDA-MB-157 Hypotriploid 837 (T 3 C)b Homozygous
MDA-MB-231 Aneuploid No change
MDA-MB-361 Lane 1 Hyperdiploid to hypodiploid No change
MDA-MB-435s Lane 2 Aneuploid No change
SK-BR-3 Lane 9 Hypertriploid to hypotetraploid No change
SUM-44PE Aneuploid No change
SUM-52PE Aneuploid No change
SUM-102PT Aneuploid 751 (G 3 A)b Heterozygous
SUM-149PT Lane 11 Aneuploid No change
SUM-159PT Lane 12 Near diploid 751 (G 3 A)b Heterozygous
SUM-185PE Aneuploid No change
SUM-190PT 751 (G 3 A)b Homozygous
SUM-225CWN No change
SUM-229PE No change
SUM-1315MO2 Lane 13 Aneuploid 751 (G 3 A)b Homozygous
Locations of nucleotide changes are denoted as follows: aimmortalized normal breast epithelial cell lines; bsequence variants in the 39UTR; cdeletion
in coding region.
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quence variant in one line with a very low level of
MAD2L1 expression, Hs 578T, suggests that we were
able to detect at least some sequence alterations in
lines with low MAD2L1 expression using an RT-
PCR–based mutation screening approach.
Our studies to date suggest that additional analysis
of the role of MAD2L1 in chromosome instability and
mammary tumor progression is warranted. The role
of MAD2L1 in breast cancer remains to be deter-
mined by further analysis in primary tumors as well as
functional assays in vitro and in vivo.
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